Submit Deal

NEWPATH PARTNERS

HQ - Boston, MA

Summary

Newpath Partners is a stage agnostic investment fund. We focus on aligning interests for academics, founders, and investors.

Deals Overview

Total Deals6

Valued Deals6

Total Value£ 984 M

Avg. Deal Size£ 164 M

Market Context

Senior Management

Nathan Sinnott
Founder & CEO
Daniel Yadegar
Chief Medical Officer & Co-founder
Thomas Cahill
Founder and Managing Partner

Sort

prime medicine

HQ - United States

Biotechnology

13 Jul 2021

Investment Date

£ 227 M

Deal Value

chroma medicine

HQ - United States

Biotechnology

17 Nov 2021

Investment Date

£ 93 M

Deal Value

neumora therapeutics

HQ - United States

Biotechnology

11 Oct 2022

Investment Date

£ 101 M

Deal Value

orbital therapeutics

HQ - United States

Biotechnology

26 Apr 2023

Investment Date

£ 216 M

Deal Value

chroma medicine

HQ - United States

Biotechnology

1 Mar 2023

Investment Date

£ 111 M

Deal Value

metsera

HQ - United States

Health Care Services

18 Apr 2024

Investment Date

£ 232 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy